Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase Ib safety data for OPT-302 in DME support progression to phase IIa

July 26, 2018

Phase I study data support biosimilarity criteria of GBR-310 to reference omalizumab

July 26, 2018

Destiny Pharma reports encouraging phase I safety data for XF-73

July 26, 2018

Corbus plans phase III trial of lenabasum in dermatomyositis

July 26, 2018

Bioasis announces positive results from microdialysis mouse study of xB3-001

July 26, 2018

ALTA-1L phase III study of brigatinib meets primary endpoint

July 26, 2018

Henan Metab Biopharma divulges Mcl-1 inhibitors

July 26, 2018

Shanghai Fochon Pharmaceutical Co., Fochon Pharma patent Bcl-2 inhibitors

July 26, 2018

New phosphodiesterase PDE2A inhibitors presented by Dart NeuroScience

July 26, 2018

Intra-Cellular Therapies identifies mu-opioid receptor antagonists

July 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...